ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)
Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels
✍ Scribed by Takashi Saika; Tomoyasu Tsushima; Yasutomo Nasu; Nobuyuki Kusaka; Yoshiyuki Miyaji; Hitoshi Takamoto; Katsuji Takeda; Satoru Uno; Hiromi Kumon; for the Okayama Urological Cancer Collaborating Group
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 182 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Prostate specific antigen (PSA) is a zymogen of a 33-kilodalton (kD) serine proteinase with extensive similarity to glandular kallikreins. The mechanism responsible for converting the zymogen into active proteinase has not been defined, but active PSA may be irreversibly inactivated in v
## Background: Prostate-specific antigen (psa) is a good objective measure of tumor cell burden or virulence of disease, or both, in prostate cancer. many differences between whites and african americans (aa) have been noted in prostate cancer in the united states, including a poorer outcome in afr
## BACKGROUND. To understand better the natural history and biology of prostate carcinoma occurring in Japanese patients, the authors attempted to define changes with time in prostate specific antigen (PSA) measurements in 48 men with clinically resectable T1-T3 nonmetastatic disease. ## METHODS.